Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19)

The MHRA has agreed to temporary modifications to be made to the pregnancy prevention programmes for these medicines to facilitate home pregnancy testing and remote consultations, where clinically appropriate, during the COVID-19 pandemic.

Source:

Medicines and Healthcare products Regulatory Agency